CYTOMED THERAPEUTICS LIMITED ORDINARY SHARES reports a Return on Equity (ROE) of -59.85%.

What is GDTC's dividend yield?

CYTOMED THERAPEUTICS LIMITED ORDINARY SHARES offers a dividend yield of 0.00%.

What is GDTC's Deepscope Quality Score?

Deepscope rates GDTC's overall financial quality at 23 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy GDTC?

Deepscope's AI Timing Score for GDTC is 6 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does GDTC belong to?

CYTOMED THERAPEUTICS LIMITED ORDINARY SHARES is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.

GDTC (NASDAQ) 株価分析 | CYTOMED THERAPEUTICS LIMITED ORDINARY SHARES

Stock Check Daily update data at 9:30 AM
(Price: 2026-06-05 | FS: 2025-12-31)

GDTC

CYTOMED THERAPEUTICS LIMITED ORDINARY SHARES

US:NASDAQ STOCK Healthcare >> Biotechnology News 96

USD 1.29

0.11 (9.32%) Day Change

Watchlist Portfolio Compare Chart

0.07

D/E

-59.9%

ROE

-49.1%

ROA

0.00%

Div Yield

CYTOMED THERAPEUTICS LIMITED ORDINARY SHARES
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 1.29 Price 0.11 (9.32%) Day Change	NEWS SCORE: 96

GDTC, ファンダメンタルスコアはnot good ( ファンダメンタル = 23) そしてテクニカルスコアは ...(Sign In to See)...

Loading chart...

23 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: ROEが低い
ROAが低い
ROEの伸びが低い
平均ROEが低い
ROEが昨年度比で低い
ROAがROEに比べて低い
ROAの伸びが低い
昨年度のROAが一昨年比で低い
NPMが低い
NPMの伸びが低い

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Lorem ipsum dolor sit amet

Unlock timing signals and detailed reasons

In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...

Deepscope 分析

42%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	96
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	1.29
PBV / Sector	2.22 / 4.63
Earning Per Share	-0.34

PE / Sector	N/A / 17.43
PEG or PE/Growth / Sector	N/A / 0.53
Average 1M Daily Value	0.03 M GREAT
Average 1W Daily Value	5563.008200000000

Timing Factors

71%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

45%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

ポイントになる統計

52%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	-1,227.07 / 449.48
NPM Average (%) / Sector	-1,644.12 / -1,506.49
NPM Change Average (%) / Sector	95.03 / 4,940.99 GREAT
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-49.05 / 30.58
ROA Average (%) / Sector	-41.55 / -347.17
ROA Change Average (%) / Sector	8.63 / 5,125.52
ROE (%) / Sector	-59.85 / -3.58
ROE Average (%) / Sector	-160.85 / 40.65
ROE Change Average (%) / Sector	-2.07 / 2,109.80
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

配当

Dividend (%) / Sector	N/A / 0.05
Dividend Average (%) / Sector	N/A / 16.49
Dividend Change Average (%) / Sector	N/A / 4.17

登録情報

Analyze Date	2026-06-06 09:09:25
Symbol	GDTC
Name	CYTOMED THERAPEUTICS LIMITED ORDINARY SHARES
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	11.83 M
Par Value	N/A
Calculated From	YearEnd
Sign	N/A
Market Cap (M.USD) / Sector Average	15.21 / 8,857.28

ニュース

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 1 Commonwealth Lane, Singapore, Singapore, 149544

Phone: 65 6250 7738

Website: https://w2.cytomed.sg

Sector: Healthcare >> Biotechnology

Description: CytoMed Therapeutics Limited, a clinical stage biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. The company's lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. It is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural killer T cells platform for cancer treatment; CTM-GDT, a product candidate that consists of expanded allogeneic gamma delta T cells and exploits the potential of the cells to recognize and treat a broad range of cancers; and CTM-MSC, an injectable allogeneic umbilical cord-derived mesenchymal stem cells for cartilage injury. It has research collaboration agreement with Sengkang General Hospital to provide CTM-MSC and its conditioned media for in vivo studies and Phase I clinical trial in Singapore; and Business and Research Collaboration Agreement with SunAct Cancer Institute Private Limited to conduct clinical trials for the GMP grade CTM-GDT. CytoMed Therapeutics Limited was incorporated in 2018 and is headquartered in Singapore.